Sanofi will sell commercial rights of some OTC products to Ipsen

Source: dingxiangyuan on February 15, 2017, Sanofi announced that it would sell commercial rights in some European regions of five consumer health products to French pharmaceutical manufacturer Ipsen, which would help to promote the asset swap transaction between Sanofi and bringer Ingelheim Ispen said it would pay 83 million euros ($88 million) in cash to access these consumer health products in some parts of Europe, of which it considers the most important to be prontaldine, an analgesic for moderate to severe pain, which has seen sales increase in double-digit percentages over the past four years and only in France The product portfolio to be traded also includes the antispasmodic Buscopan, the laxative supplestoriaglycorini, and the cough and flu drugs mucothiol and mucodyne, which are sold across eight European countries, ispen said The deal, which is subject to customary conditions, including approval from the European Commission, is expected to be completed in the second quarter of this year Fabre, Ipsen's executive vice president of basic healthcare, said the new assets will expand the company's over-the-counter portfolio and enhance its value proposition to consumers These products are fully compatible with our existing basic resources, of which prontagine, the main product, is based on a mature and growing French pain medication market, with a 30% market share, which will help us reach key sales targets in the pharmacy channel and accelerate the development of our consumer healthcare business From Sanofi's point of view, the move comes as the European Commission asked it to divest certain assets in order to reach a proposed consumer healthcare asset swap with bringer Last June, the two companies announced plans to replace Sanofi's 11.4 billion euro animal health business (Merial) and bringer's 6.7 billion euro consumer health business